【港股异动 | CRO概念股持续走高新药临床试验加速利好CRO企业机构称板块补涨动力充足】智通财经APP获悉，CRO

智通财经2025-06-30

【港股异动 | CRO概念股持续走高新药临床试验加速利好CRO企业机构称板块补涨动力充足】智通财经APP获悉，CRO概念股持续走高，截至发稿，昭衍新药(06127.HK)涨13.73%，报17.56港元；泰格医药(03347.HK)涨6.03%，报37.8港元；凯莱英(06821.HK)涨4.7%，报77.9港元；药明生物(02269.HK)涨2.39%，报25.75港元。

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2547030258?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-06-30 11:23","share_image_url":"https://static.laohu8.com/6ca2dcdccfa2217fb20a0351f4efe814","id":"2547030258","market":"hk","top_or_hot":-1,"title":"【港股异动 | CRO概念股持续走高 新药临床试验加速利好CRO企业 机构称板块补涨动力充足】智通财经APP获悉，CRO","media":"智通财经","content":"<div>\n<p>【港股异动 | CRO概念股持续走高 新药临床试验加速利好CRO企业 机构称板块补涨动力充足】智通财经APP获悉，CRO概念股持续走高，截至发稿，昭衍新药(06127.HK)涨13.73%，报17.56港元；泰格医药(03347.HK)涨6.03%，报37.8港元；凯莱英(06821.HK)涨4.7%，报77.9港元；药明生物(02269.HK)涨2.39%，报25.75港元。</p>\n\n<a href=\"https://www.zhitongcaijing.com/immediately.html?type=ganggu\">网页链接</a>\n\n</div>\n","source":"live_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>【港股异动 | CRO概念股持续走高 新药临床试验加速利好CRO企业 机构称板块补涨动力充足】智通财经APP获悉，CRO</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n【港股异动 | CRO概念股持续走高 新药临床试验加速利好CRO企业 机构称板块补涨动力充足】智通财经APP获悉，CRO\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-06-30 11:23 北京时间&nbsp;&nbsp;&nbsp;<a href=https://www.zhitongcaijing.com/immediately.html?type=ganggu><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>【港股异动 | CRO概念股持续走高 新药临床试验加速利好CRO企业 机构称板块补涨动力充足】智通财经APP获悉，CRO概念股持续走高，截至发稿，昭衍新药(06127.HK)涨13.73%，报17.56港元；泰格医药(03347.HK)涨6.03%，报37.8港元；凯莱英(06821.HK)涨4.7%，报77.9港元；药明生物(02269.HK)涨2.39%，报25.75港元。</p>\n\n<a href=\"https://www.zhitongcaijing.com/immediately.html?type=ganggu\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0516423174.USD","symbol_name":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"I\" (USD) ACC","start_time":0,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","article_id":"2547030258","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2547030258","pubTimestamp":1751253800,"columns":[],"sourceInfo":{"source_id":"live_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"【港股异动 | CRO概念股持续走高 新药临床试验加速利好CRO企业 机构称板块补涨动力充足】智通财经APP获悉，CRO概念股持续走高，截至发稿，昭衍新药(06127.HK)涨13.73%，报17.5","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"300347":"泰格医药","603127":"昭衍新药","LU0516423174.USD":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"I\" (USD) ACC","LU1146622755.USD":"安本中国A股股票基金A Acc","LU0039217434.USD":"HSBC GIF CHINESE EQUITY \"AD\" INC","06821":"凯莱英","BK1576":"医药外包概念","BK0028":"国家队","06127":"昭衍新药","LU0140636845.USD":"施罗德大中华区股票A Acc","BK1191":"制药","LU0823426480.USD":"法巴中国股票经典Dis","LU0043850808.USD":"HSBC GIF ASIA EX JAPAN EQUITY \"AD\" INC","LU0823426308.USD":"法巴中国股票基金","LU1242518931.SGD":"Fullerton Lux Funds - Asia Absolute Alpha A Acc SGD","LU0417516738.SGD":"Allianz Hong Kong Equity AT Acc SGD","LU0856984785.SGD":"HSBC GIF MANAGED SOLUTIONS ASIA FOCUSED GROWTH \"ACH\" (SGDHDG) ACC","LU0348735423.USD":"ALLIANZ HONG KONG EQUITY \"A\" (USD) INC","LU1880383366.USD":"东方汇理中国股票基金 A2 (C)","LU0359201612.USD":"贝莱德中国基金A2","LU1328615791.USD":"FULLERTON LUX FUNDS - ALL CHINA EQUITIES \"I\" (USD) ACC","LU0456846285.SGD":"JPMorgan Funds - Greater China A (acc) SGD","LU0516422366.SGD":"Fullerton Lux Funds - Asia Focus Equities A Acc SGD","LU0359202008.SGD":"Blackrock China Fund A2 SGD-H","LU0051755006.USD":"摩根大通中国A (dist)","LU0819121731.USD":"HSBC GIF MANAGED SOLUTIONS ASIA FOCUSED GROWTH \"AC\" (USD) ACC","LU0979878070.USD":"FULLERTON LUX FUNDS - ASIA ABSOLUTE ALPHA \"A\" (USD) ACC","LU1688375341.USD":"贝莱德中国灵活股票基金","LU1720050803.USD":"安联全方位中国股票基金","LU0326950275.SGD":"Schroder ISF China Opportunities A Acc SGD-H","002821":"凯莱英","BK0216":"研究试验","LU0181495838.USD":"施罗德新兴亚洲A Acc","BK1583":"高瓴概念","BK0239":"医药制造","LU0456827905.SGD":"JPMorgan Funds - China A (acc) SGD","LU0417516902.SGD":"Allianz China Equity Cl AT Acc SGD","LU0516423091.SGD":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"I\" (SGD) ACC","BK1521":"挪威政府全球养老基金持仓","BK0077":"质押式回购","LU0052750758.USD":"富兰克林中国基金A Acc","LU0320764599.SGD":"FTIF - Templeton China A Acc SGD","IE00B0JY6N72.USD":"PINEBRIDGE GLOBAL EMERGING MARKETS FOCUS EQUITY \"A\" (USD) ACC","BK1141":"生命科学工具和服务","02269":"药明生物","LU0708995583.HKD":"TEMPLETON CHINA \"A\" (HKD) ACC","BK1589":"北水核心资产","03347":"泰格医药","LU0516422440.USD":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"A\" (USD) ACC","LU0327786744.USD":"Janus Henderson Horizon China Opportunities A2 USD"},"translate_title":"[Hong Kong stocks change, CRO concept stocks continue to rise, and the acceleration of clinical trials of new drugs is good for CRO companies. Institutions say the sector has sufficient momentum to make up for the gains] Zhitong Finance APP learned that CRO","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"300347":1,"603127":1,"002821":1,"06821":1,"06127":1,"03347":1,"02269":1},"content_text":"【港股异动 | CRO概念股持续走高 新药临床试验加速利好CRO企业 机构称板块补涨动力充足】智通财经APP获悉，CRO概念股持续走高，截至发稿，昭衍新药(06127.HK)涨13.73%，报17.56港元；泰格医药(03347.HK)涨6.03%，报37.8港元；凯莱英(06821.HK)涨4.7%，报77.9港元；药明生物(02269.HK)涨2.39%，报25.75港元。","kind":"live","is_publish_news":false,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2547030258","isCrawlerRequest":true}

【港股异动 | CRO概念股持续走高 新药临床试验加速利好CRO企业 机构称板块补涨动力充足】智通财经APP获悉，CRO

精彩评论

【港股异动 | CRO概念股持续走高新药临床试验加速利好CRO企业机构称板块补涨动力充足】智通财经APP获悉，CRO